Aurealis Therapeutics is a swiss-finnish private biopharmaceutical company that specializes in cell and gene therapies for chronic wounds.
Aurealis Therapeutics has raised $9.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2024.
Aurealis Therapeutics's investors include Tesi, Lynx Capital, Zhejiang Huahai Pharmaceutical.
Aurealis Therapeutics is headquartered in Kuopio, Finland.
Aurealis Therapeutics is a swiss-finnish private biopharmaceutical company that specializes in cell and gene therapies for chronic wounds.
Aurealis Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aurealis Therapeutics — Funding & Investors." VCBacked, November 13, 2024, https://www.vcbacked.co/company/aurealis-therapeutics. Accessed August 16, 2026.
VCBacked. (2024). Aurealis Therapeutics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/aurealis-therapeutics
{{cite web |title=Aurealis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aurealis-therapeutics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated